TD Asset Management Inc Increases Stock Holdings in Abbott Laboratories $ABT

TD Asset Management Inc raised its stake in shares of Abbott Laboratories (NYSE:ABT) by 21.1% during the second quarter, Holdings Channel reports. The firm owned 1,423,665 shares of the healthcare product maker’s stock after buying an additional 248,360 shares during the quarter. TD Asset Management Inc’s holdings in Abbott Laboratories were worth $129,183,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. MidAtlantic Capital Management Inc. purchased a new position in shares of Abbott Laboratories during the fourth quarter valued at about $25,000. Cornerstone Financial Management LLC purchased a new stake in Abbott Laboratories in the fourth quarter worth about $25,000. Purpose Unlimited Inc. bought a new stake in Abbott Laboratories during the 4th quarter valued at approximately $25,000. Portfolio Resources Advisor Group Inc. bought a new stake in Abbott Laboratories during the 4th quarter valued at approximately $26,000. Finally, Abound Financial LLC purchased a new position in shares of Abbott Laboratories during the 4th quarter worth approximately $26,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: New diabetes-device opportunity: Medtronic has begun shipping its MiniMed Flex insulin pump, which uses an Abbott-made glucose sensor. The launch and accompanying marketing campaign could expand Abbott’s sensor presence in the growing diabetes-care market. MiniMed starts shipping new insulin pump with Abbott-made sensor
• Positive Sentiment: Underlying business remains diversified: Analyst commentary highlights Abbott’s established diagnostics, medical-device and nutrition franchises, along with long-term growth opportunities. Its latest reported quarter also exceeded consensus earnings and revenue estimates, with revenue up 13% year over year. Ken Griffin Just Loaded Up on AbbVie and Abbott
• Neutral Sentiment: Formula litigation clarity: Abbott agreed to pay approximately $670 million to resolve the Gill case and about 2,000 additional necrotizing-enterocolitis claims without admitting liability. The settlement is costly, but it removes uncertainty tied to a large jury award and provides greater visibility into remaining litigation exposure. How Investors Are Reacting To Abbott Laboratories US$670 Million NEC Settlement
• Neutral Sentiment: Investor comparisons are favorable but valuation-sensitive: Articles describe Abbott as a potential long-term healthcare and dividend investment, though comparisons with Envista, Intuitive Surgical, Thermo Fisher and Johnson & Johnson emphasize differing growth, recovery and valuation profiles. NVST or ABT: Which Is the Better Value Stock Right Now?
• Negative Sentiment: Diagnostics growth is uneven: Weaker respiratory-testing demand is offsetting healthy routine testing and approximately 13% growth in cancer diagnostics. This mix could moderate near-term Diagnostics momentum despite strength in higher-growth categories. Here’s What Is Shaping Abbott’s Diagnostics Growth

Abbott Laboratories Stock Up 0.1%

ABT stock opened at $116.70 on Tuesday. The business has a 50 day moving average of $100.64 and a 200 day moving average of $100.03. The firm has a market cap of $201.94 billion, a PE ratio of 37.77, a price-to-earnings-growth ratio of 2.26 and a beta of 0.59. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $137.49. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The firm had revenue of $12.59 billion for the quarter, compared to analysts’ expectations of $12.52 billion. During the same period in the prior year, the firm posted $1.26 earnings per share. The company’s quarterly revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, research analysts forecast that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th were paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date was Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 81.55%.

Wall Street Analyst Weigh In

A number of research firms have recently commented on ABT. UBS Group lowered their target price on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a research note on Tuesday, July 28th. Weiss Ratings upgraded Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, August 6th. Bank of America dropped their target price on shares of Abbott Laboratories from $120.00 to $102.00 in a report on Friday, June 12th. Robert W. Baird started coverage on shares of Abbott Laboratories in a research report on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 target price on the stock. Finally, TD Cowen reissued a “buy” rating and set a $115.00 price target on shares of Abbott Laboratories in a research report on Friday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $118.67.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.